This transcript has been edited for clarity. Gayatri Acharya, MD: Greetings. I'm Dr Gayatri Acharya, cardiology fellow at Mayo Clinic. During today's roundtable, we'll be discussing cardiac ...

The diagnosis of cardiac ATTR amyloidosis is frequently missed or delayed due to the transitional requirement that a tissue sample (biopsy) is required to confirm the diagnosis. A nuclear medicine ...

Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.

An amyloidosis diagnosis can take upwards of 2 years.Initial symptoms often are nondescript, and irreversible organ damage frequently occurs before disease confirmation.

Screening for cardiac amyloidosis and excluding patients with cardiac amyloidosis from trials of new therapies for heart failure with preserved ejection fraction (HFpEF) may increase the chances of ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...

Transthyretin cardiac amyloidosis (ATTR-CA) is a frequent cause of heart failure (HF) in older Black individuals, particularly in the oldest men, the prospective SCAN-MP study affirms. The highest ...

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues ...

Nuclear cardiologists are protesting the US Centers for Medicare & Medicaid Services potential 57% reimbursement cuts for pyrophosphate (PYP)/amyloid imaging, mere days before the comment period on ...